US Stock MarketDetailed Quotes

CLLS Cellectis

Watchlist
  • 1.530
  • +0.020+1.32%
Close Jan 22 16:00 ET
  • 1.530
  • 0.0000.00%
Post 19:50 ET
153.14MMarket Cap-1.31P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Nov 5, 2024 15:31
    NEWS
    $Cellectis (CLLS.US)$
    Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
    Cellectis announced pre-clinical data presentation at SITC's 39th Annual Meeting, showcasing strategies to enhance CAR T-cell efficacy against solid tumors. The research focuses on overcoming challenges in the tumor microenvironment (TME) using TALEN®-mediated gene editing to generate allogeneic CAR T-cells. The company developed two key approaches: a FAP-depe...
    Jaguar8
    Jaguar8
    Nov 4, 2024 22:08
    ER THIS AM
    $Cellectis (CLLS.US)$
    Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
    Positive
    Strong cash position of $264 million with runway extended into 2027
    Significant revenue increase to $34.1 million, up from $7.2 million YoY
    Net loss improved to $42.7 million from $59.3 million YoY
    Secured $47 million in payments from AstraZeneca partnership
    Negative
    R&D expenses increased to $69.7 million from $62.7 million YoY
    SG&A expenses rose to $14.2 million from $12....
    Trytosaveabit
    Trytosaveabit
    Nov 4, 2024 17:01
    Expected more of a move! Hehehe
    $Cellectis (CLLS.US)$ Cellectis GAAP EPS of -$0.23 misses by $0.02, revenue of $18.05M beats by $8.95M
    Jaguar8
    Jaguar8
    Oct 22, 2024 01:00
    NEWS
    $Cellectis (CLLS.US)$
    Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
    Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on TALE base editors (TALEB) and non-viral gene insertion at the European Society of Cell and Gene Therapy 31st annual congress in Roma, Italy, from October 22-25, 2024. Two posters will be showcased:
    1. 'Controlling C-to-T editing with TALE base editors' by Alexandre Juillerat, Ph.D....
    Trytosaveabit
    Trytosaveabit
    Sep 3, 2024 15:36
    Update
    $Cellectis (CLLS.US)$ Benzinga· 4 mins ago
    Cellectis Presents Pre-Clinical Evidence That TALEN-Edited MUC1 CAR T-Cells Reduce Triple-Negative Breast Cancer While Ensuring Safety
Read more

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
Fuling Technology
001356
+371.32%
KLT
831689
+23.60%
Hand Enterprise Solutions
300170
+20.00%
4
Kinco Automation (Shanghai) Co.,Ltd
688160
+17.15%
5
Doushen(Beijing) Education & Technology Inc.
300010
+16.32%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.
Discussing
As Tesla's earnings near, will its stock soar?
🎙️Discussion: 1. With Trump's return, can Tesla's stock price continue to rise in 2025? 2. Tesla is set to release its earnings report aft Show More
🚗 Tesla Q4 Dip: Time to Buy , or Is the Risk Too High? 📉